IGF1 and breast carcinoma: These studies are important since the breast cancers from populations of women at high risk have elevated levels of circulating IGF-1 (e.g. women with BRCA1 mutations) are more difficult to treat/manage due to their aggressive nature and because the patients are often not candidates for standard endocrine therapy [24-26].